DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Radiotherapy IT company CruxQS acquires RDS Will expand footprint for FlowBoard workflow management system

New model boosts flow efficiency of particle accelerators May lead to smaller accelerators, easier to operate at reduced costs

Why are breast cancer survivors foregoing recommended screening? Study finds poor adherence to annual mammogram guidelines

Is low cost Proton-to-Carbon Heavy Ion radiotherapy coming soon? Best Particle Therapy plans to bring smaller footprint system to market in two to three years

Researchers develop AI approach for high-risk clinical tumor volumes Assisting low- and middle-income countries that lack contouring expertise

Dr. Benjamin Movsas American Radium Society Names president-elect

Tennessee governor vetoes state employee proton therapy coverage Would require PT to be covered under the same aggregate amount as IMRT

AI approach used to study Mars now assessing tumor response to therapies Could reduce sample sizes and accelerate process for approval of cancer therapies

European medical center first to perform linac-based MR-guided RT using on-table adaptation Made possible with ViewRay's MRIdian Linac

Hospital in Italy performs radiosurgery with Brainlab's Elements Spine SRS software Automatically plans treatments for complex parts of the body

The University of Virginia Health System
is conducting the first clinical trial
that combines focused ultrasound and
immunotherapy

Clinical trial combining focused ultrasound and immunotherapy underway

by John R. Fischer , Staff Reporter
A first-of-its-kind trial seeks to combine two forms of therapy for the treatment of stage IV breast cancer.

Researchers at the University of Virginia (UVA) Health System are conducting a clinical trial that combines noninvasive focused ultrasound technology through the use of Theraclion’s Echopulse system with an immunotherapy medication, pembrolizumab.

Story Continues Below Advertisement

Breast Health Solutions

Innovative AI software solutions built on deep learning for breast tomosynthesis, breast density and 2D mammography. Learn more>



“The idea behind focused ultrasound is that it’s a way to do surgery without incisions,” Patrick Dillon, associate professor of hematology and oncology at UVA, told HCB News. “In this case, it has been shown to exhibit a degree of immune recognition of tumors. The pembrolizumab is a PD-1 inhibiting antibody, which essentially means that it kind of takes the brakes off the immune system, thereby allowing for greater immune recognition of disease cells or cancer cells in this case.”

The immune system does not recognize most breast cancers as foreign cells, and therefore, does not trigger immune responses to combat them. Immunotherapy has also historically been more successful in treating other forms of cancer, compared to breast.

The aim of the trial is to observe if the combined use of focused ultrasound and pembrolizumab will enhance the ability of the immune system to recognize tumors in fifteen women participants who have been randomized to receive the medication before or following focused ultrasound treatment. Using an ultrasound probe of the Echopulse system, researchers will apply thermal energy to a target, physically heat up, and destroy up to fifty percent of the tumor.

The idea, according to Dillon, is that the ultrasound will expose some of the protein antigens to the dendritic cells of the immune system, triggering an immune response from the tumor at the same time that the tumor cells are destroyed. The addition of the pembrolizumab will allow the ultrasound to enhance immune recognition of the tumor locally in the breast and more importantly, of cancer cells in the rest of the body.

Dillon says that though it is too early to predict the results of the trial, he is optimistic in the insight it will provide on the immunological treatment of breast cancer.

“I expect that we would see at least additive if not synergistic response to this combination therapy,” he said. That’s our primary endpoint, to look specifically at the types of T cells infiltrating in the tumor. We’re looking to see if we are augmenting the T cell response, the immune response in the tumor site.”

Theraclion recently chose EDAP TMS SA to distribute the Echopulse system, which is CE-marked for treating breast fibroadenomas, thyroid nodules and other conditions, throughout France.

The system is not yet FDA approved. Pembrolizumab is not either, and is considered investigational for the purpose of the study.

The trial is currently underway and is funded, in part, by the Focused Ultrasound Foundation and the Commonwealth of Virginia. Researchers are currently looking for enrollees for the next year.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED